Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy

Cancer Gene Therapy

Volumn 18, Issue 6, 2011, Pages 435-443

  Leveille, S ^a,b   Samuel, S ^a,b   Goulet, M L ^a   Hiscott, J ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

5FC; combination therapy; oncolysis; suicide gene; synergism; VSV

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; ONCOLYTIC VIRUS; PRODRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE THERAPY; TREATMENT RESPONSE; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; ONCOLYTIC VIRUSES; PENTOSYLTRANSFERASES; RECOMBINANT FUSION PROTEINS; VESICULOVIRUS;

ANIMALIA; VESICULAR STOMATITIS VIRUS;

EID: 79956142299     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.14     Document Type: Article

References (35)

1. Rowan K. Oncolytic viruses move forward in clinical trials. J Natl Cancer Inst 2010; 102: 590-595.
2. Bell J. Oncolytic viruses: an approved product on the horizon? Mol Ther 2010; 18: 233-234.
3. Cattaneo R, Miest T, Shashkova EV, Barry MA. Repro-grammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540. (Pubitemid 351850977)
4. Barber GN. VSV-tumor selective replication and protein translation. Oncogene 2005; 24: 7710-7719. (Pubitemid 41670673)
5. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004; 10: 210-216. (Pubitemid 38581793)
6. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275. (Pubitemid 37329791)
7. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825. (Pubitemid 30469434)
8. Nguyen TL, Tumilasci VF, Singhroy D, Arguello M, Hiscott J. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol 2009; 11: 889-897.
9. Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008; 105: 14981-14986.
10. Tumilasci VF, Oliere S, Nguyen TL, Shamy A, Bell J, Hiscott J. Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 2008; 82: 8487-8499.
11. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 2010; 107: 1576-1581.
12. Schache P, Gurlevik E, Struver N, Woller N, Malek N, Zender L et al. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther 2009; 16: 849-861.
13. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007; 28: 4-41.
14. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombi-nant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 1995; 92: 4477-4481.
15. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895-904. (Pubitemid 34033386)
16. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007; 110: 2342-2350. (Pubitemid 47523154)
17. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359. (Pubitemid 40434601)
18. Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15: 1361-1371.
19. Koyama F, Sawada H, Hirao T, Fujii H, Hamada H, Nakano H. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015-1022. (Pubitemid 30483481)
20. Liu Y, Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther 2006; 13: 845-855.
21. Khatri A, Zhang B, Doherty E, Chapman J, Ow K, Pwint H et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 2006; 8: 1086-1096. (Pubitemid 44480401)
22. Porosnicu M, Mian A, Barber GN. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phos-phoribosyltransferase suicide gene. Cancer Res 2003; 63: 8366-8376. (Pubitemid 37549491)
23. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 2003; 77: 4646-4657. (Pubitemid 36402814)
24. Faria PA, Chakraborty P, Levay A, Barber GN, Ezelle HJ, Enninga J et al. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 2005; 17: 93-102. (Pubitemid 40075368)
25. Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immuno-stimulatory tumor therapy. Cancer Res 2005; 65: 4343-4352. (Pubitemid 40775673)
26. Oliere S, Arguello M, Mesplede T, Tumilasci V, Nakhaei P, Stojdl D et al. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008; 82: 5735-5749. (Pubitemid 351822249)
27. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Sakamoto T et al. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer 1999; 81: 592-597. (Pubitemid 29203058)
28. Chou TC and Talalay. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
29. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15: 1686-1693. (Pubitemid 47289013)
30. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G et al. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 2010; 17: 158-170.
31. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-4626. (Pubitemid 23304389)
32. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000; 44: 938-942. (Pubitemid 30165273)
33. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1999; 96: 9821-9826. (Pubitemid 29398816)
34. Byfield JE, Murnane J, Ward JF, Calabro-Jones P, Lynch M, Kulhanian F. Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. Br J Cancer 1981; 43: 669-683.
35. te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW. Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob Agents Chemother 2005; 49: 4220-4226. (Pubitemid 41400967)